AUGUST 2017 • VOLUME 17-03
PHARMACISTS' EDITION

NOVA SCOTIA

PharmacareNEWS

inside

Nova Scotia Formulary Updates

New Exception Status Benefits
- Forxiga (dapagliflozin)
- Xigduo (dapagliflozin and metformin hydrochloride)

Criteria Update: Antipsychotic Medications
- Abilify (aripiprazole)
- Latuda (lurasidone)
- Zeldox (ziprasidone)
- Abilify Maintena (aripiprazole)
- Invega Sustenna (paliperidone)
- Risperdal Consta (risperidone)

Changes in Benefit Status

New Products

Nova Scotia Formulary Updates

New Exception Status Benefits

The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and were listed with the following criteria effective **August 1, 2017.**

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Forxiga	5mg Tab	02435462	DNP	E (SF)	AZE
(dapagliflozin)	10mg Tab	02435470	DNP	E (SF)	AZE
Criteria	• For the treatment of Type II diabetes when: ○ Added on to metformin for patients: ▪ Who have inadequate glycemic control on metformin and ▪ Who have a contraindication or intolerance to a sulfonylurea and ▪ For whom insulin is not an option ○ Added on to a sulfonylurea for patients: ▪ Who have inadequate glycemic control on a sulfonylurea and ▪ Who have a contraindication or intolerance to metformin and ▪ For whom insulin is not an option				

New Exception Status Benefits Continued…

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Xigduo (dapagliflozin and metformin hydrochloride)	5mg/850mg Tab 5mg/1000mg Tab	02449935 02449943	DNP DNP	E (SF) E (SF)	AZE AZE

Criteria	• For the treatment of Type II diabetes for patients:
	  ○ Who are already stabilized on therapy with dapagliflozin and metformin to replace the individual components of dapagliflozin and metformin; and
	  ○ For whom insulin is not an option
	Claim Note:
	• Must have met criteria for dapagliflozin				

Criteria Updates: Antipsychotic Medications

The following criteria updates were effective **August 1, 2017.**

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Abilify (aripiprazole)	2mg Tab	02322374	DNP	E (SF)	BRI
	5mg Tab	02322382	DNP	E (SF)	BRI
	10mg Tab	02322390	DNP	E (SF)	BRI
	15mg Tab	02322404	DNP	E (SF)	BRI
	20mg Tab	02322412	DNP	E (SF)	BRI
	30mg Tab	02322455	DNP	E (SF)	BRI
Latuda (lurasidone)	20mg Tab	02422050	DNP	E (SF)	SNV
	40mg Tab	02387751	DNP	E (SF)	SNV
	60mg Tab	02413361	DNP	E (SF)	SNV
	80mg Tab	02387778	DNP	E (SF)	SNV
	120mg Tab	02387786	DNP	E (SF)	SNV
Zeldox (ziprasidone)	20mg Cap	02298597	DNP	E (SF)	PFI
	40mg Cap	02298600	DNP	E (SF)	PFI
	60mg Cap	02298619	DNP	E (SF)	PFI
	80mg Cap	02298627	DNP	E (SF)	PFI
Criteria	• For the treatment of schizophrenia and related psychotic disorders (not dementia related) in patients with a history of failure, intolerance, or contraindication to at least one less expensive antipsychotic agent				

Criteria Updates: Antipsychotic Medications Continued…

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Abilify Maintena	300mg Vial Inj	02420864	DNP	E (SF)	OTS
(aripiprazole)	400mg Vial Inj	02420872	DNP	E (SF)	OTS
Invega Sustenna	50mg/0.5mL Inj	02354217	DNP	E (SF)	JAN
(Paliperidone)	75mg/0.75mL Inj	02354225	DNP	E (SF)	JAN
	100mg/mL Inj	02354233	DNP	E (SF)	JAN
	150mg/1.5mL Inj	02354241	DNP	E (SF)	JAN
Risperdal Consta	12.5mg/2mL Inj	02298465	DNP	E (SF)	JAN
(Risperidone)	25mg/2mL Inj	02255707	DNP	E (SF)	JAN
	37.5mg/2mL Inj	02255723	DNP	E (SF)	JAN
	50mg/2mL Inj	02255758	DNP	E (SF)	JAN
Criteria	• For the maintenance treatment of schizophrenia and related psychotic disorders (not dementia related) in patients who are not adherent to an oral antipsychotic OR • Who are currently receiving a long-acting injectable antipsychotic and require an alternative long acting injectable antipsychotic				

Changes in Benefit Status

Effective **August 1, 2017,** the following products have moved to full benefit status.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
amphetamine XR (Adderall XR)	5mg Cap	Various	DNP	SFC	VAR
amphetamine XR (Adderall XR)	10mg Cap	Various	DNP	SFC	VAR
amphetamine XR (Adderall XR)	15mg Cap	Various	DNP	SFC	VAR
amphetamine XR (Adderall XR)	20mg Cap	Various	DNP	SFC	VAR
amphetamine XR (Adderall XR)	25mg Cap	Various	DNP	SFC	VAR
amphetamine XR (Adderall XR)	30mg Cap	Various	DNP	SFC	VAR
Clopixol	10mg Tab	02230402	DNP	SF	VLH
Clopixol	25mg Tab	02230403	DNP	SF	VLH
Intron A (albumin free)	6,000,000iu/mL Inj	02238674	DNP	SFC	FRS
Intron A (albumin free)	10,000,000iu/mL Inj	02238675	DNP	SFC	FRS
Intron A	10,000,000iu/vial Inj	02223406	DNP	SFC	FRS

Changes in Benefit Status Continued…

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Intron A	15,000,000iu Multidose Pen	02240693	DNP	SFC	FRS
Intron A	25,000,000iu Multidose Pen	02240694	DNP	SFC	FRS
Intron A	50,000,000iu Multidose Pen	02240695	DNP	SFC	FRS
Pegasys	180mcg/0.5mL Syr Inj	02248077	DNP	SF	HLR
Pegasys Proclick Autoinjector	180mcg/0.5mL Syr Inj	02248077	DNP	SF	HLR
Valganciclovir (Valcyte)	450mg Tab	Various	DNP	SF	VAR

Effective **August 1, 2017,** the following products have moved to exception status and will require special authorization. Existing criteria will apply.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Cetirizine (Reactine)	20mg Tab	Various	DNP	E (SF)	VAR

Effective **August 1, 2017,** the following products have moved to non-benefit status and will no longer be covered under the Nova Scotia Pharmacare Programs.

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Alcaine	0.5% Drops	00035076	**Not Insured**	ALC
Proglycem	100mg Cap	00503347	**Not Insured**	FRS
Reactine	5mg Tab	02223546	**Not Insured**	JNJ

New Products

The following new products have been added to the Nova Scotia Formulary, effective **August 1, 2017**. The benefit status within the Nova Scotia Pharmacare Programs is indicated and any existing criteria will apply.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Asmanex Twisthaler	100mcg/metered Inh	02438690	DNP	F*	FRS
Creon Minimicrospheres MICRO	5000 units/5100 units/320 units	02445158	DNP	SF	BGP
Dovobet	50mcg/g/0.5mg/g Gel (with Applicator)	02319012	DNP	E (SF)	LEO
Jamp Citalopram	10mg Tab	02370085	DNP	SFC	JPC
Mint-Citalopram	10mg Tab	02429691	DNP	SFC	MNT
Zytiga	500mg Film-coated Tab	02457113	DNP	E (SFC)	JAN

* full benefit for children ages 4-11